Consequences of hemolytic uremic syndrome among hemodialysis patients
نویسندگان
چکیده
BACKGROUND Hemolytic uremic syndrome (HUS) is characterized by hemolytic anemia, low platelets, and renal impairment and is mediated by thrombotic microangiopathy (TMA). A common perception is that HUS becomes dormant in dialysis patients with end-stage renal disease (ESRD). We analyzed patients in a large dialysis organization to understand the potential consequences and burden of HUS. METHODS We identified patients with ESRD ascribed to HUS and those with ESRD ascribed to another cause (control patients) who received hemodialysis or peritoneal dialysis from 01 January 2007 to 31 December 2012. Outcomes were survival, hospitalization, and longitudinal laboratory values associated with TMA, including lactate dehydrogenase, red cell distribution width (RDW), platelets, and hemoglobin. RESULTS HUS patients (n = 217) were propensity-score matched 1:5 to control patients (n = 1,085) for age, gender, race, dry weight, insurance, access, comorbidities, and Charlson comorbidity index. Compared to control patients, HUS patients had significantly greater risk for hospitalizations overall (RR = 2.3, p = 0.004) and hospitalization for hematologic (RR = 5.6, p = 0.001), cardiovascular (RR = 2.1, p = 0.02), and pancreatic (RR = 7.9, p = 0.04) causes. HUS patients also had evidence of ongoing TMA: higher lactate dehydrogenase and RDW, lower platelets and hemoglobin, and more frequent lactate dehydrogenase spikes. CONCLUSIONS Dialysis patients with HUS were at significantly higher risk than matched control patients for hospitalizations due to cardiovascular, hematologic, and pancreatic disease, which were associated with ongoing TMA. Additional studies are needed to determine whether targeted therapy for HUS reduces hospitalizations.
منابع مشابه
ANALYSIS OF PROGNOSTIC FE ATURES IN CHILDREN WITH THE HEMOLYTIC-UREMIC SYNDROME
The purpose of this study has been to evaluate various factors influencing prognosis in children with hemolytic-uremic syndrome (HUS). Forty children with classical picture of HUS were seen in 1986-1 991. Boys and girls were equally affected, aged from two months to ten years. In 35 patients (87.5%) there was a history of diarrhea which was bloody in25. All were treated with peritoneal dial...
متن کاملRelationship between Pathologic and Laboratory Data of Children Suffering from Hemolytic Uremic Syndrome (HUS): A Center study
Background and objective: Hemolytic uremic syndrome (HUS) is the most prevalent cause of children renal insufficiency which in many cases (90%) occurs following diarrhea. Hemolytic microangiopathic anemia, thrombocytopenia, and renal insufficiency are main symptoms of hemolytic uremic syndrome. This stud...
متن کاملConcurrent Atypical Hemolytic Uremic Syndrome and Autoimmune Hemolytic Anemia: a case report
Background: Atypical hemolytic uremic syndrome (aHUS) is a life-threatening and scarce disorder characterized by acute renal failure and disease, non-immune microangiopathic hemolytic anemia and thrombocytopenia, leading to end-stage renal failure or death, and consequently maybe accompanying by extra renal manifestations. Case report: We reported aHUS accompanied by autoimmune hemolytic anemi...
متن کاملHemolytic uremic syndrome in children: Seizure disorders and mortality rate
Background and Objective: Hemolytic Uremic Syndrome (HUS) is a thrombotic microangiopathy that contains hemolytic anemia, thrombocytopenia, renal failure and other organ involvement including central nervous system. Frequency of neurologic complications in patients with HUS is high and important cause of mortality. This study was performed to determine seizure disorders in term of acute neurolo...
متن کاملContinued Eculizumab Therapy for Persistent Atypical Hemolytic Uremic Syndrome
Atypical hemolytic uremic syndrome (atypical HUS) is characterized by endothelial injury and microvascular thrombosis resulting in microangiopathic hemolytic anemia, thrombocytopenia, and ischemic injury to organs, especially the kidney. Activation of complements is involved in the pathogenesis of atypical HUS. Eculizumab, a neutralizing monoclonal antibody directed against complement C5, has s...
متن کامل